8-KRegulation FDExhibits & Filings

Cencora, Inc. 8-K Report, Regulation FD Disclosure (Nov 7, 2017)

Filed November 7, 2017For Securities:COR

Summary

Cencora, Inc. (formerly AmerisourceBergen) announced a significant reorganization of its operating segments, effective September 30, 2017. The company has combined its legacy AmerisourceBergen Drug Corporation and AmerisourceBergen Specialty Group into a single "Pharmaceutical Distribution Services" segment. This move aims to streamline operations and provide a more consolidated view of its core distribution business. In addition to this primary segment realignment, Cencora has also reallocated certain businesses between segments. Its non-title third-party logistics business has moved from Pharmaceutical Distribution Services to the "Other" segment (along with World Courier), while the AmerisourceBergen Consulting Services distribution business has been integrated into Pharmaceutical Distribution Services. The company explicitly states that these changes do not materially impact historical operating results, and it is providing revised segment information to aid investor analysis.

Key Highlights

  • 1Operating segment reorganization effective September 30, 2017.
  • 2Legacy AmerisourceBergen Drug Corporation and Specialty Group combined into "Pharmaceutical Distribution Services".
  • 3Non-title third-party logistics business moved from Pharmaceutical Distribution Services to "Other" segment.
  • 4AmerisourceBergen Consulting Services distribution business moved from "Other" to "Pharmaceutical Distribution Services".
  • 5Company states these changes did not materially impact historical reportable segment operating results.
  • 6Supplemental disclosure (Exhibit 99.1) of unaudited revised reportable segment information is being furnished.
  • 7Revised segment data covers fiscal quarters of 2017 and 2016, and fiscal year 2016.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce and disclose a reorganization of Cencora's (formerly AmerisourceBergen) operating segments and to provide investors with updated financial information reflecting these changes.

The company has combined two former segments (AmerisourceBergen Drug Corporation and AmerisourceBergen Specialty Group) into a new, single "Pharmaceutical Distribution Services" segment. Additionally, specific businesses have been moved between the "Pharmaceutical Distribution Services" and "Other" segments.

According to the filing, these changes are primarily structural and did not have a material impact on the company's historical reportable segment operating results.

The company is furnishing a supplemental disclosure (Exhibit 99.1) with unaudited, revised reportable segment information for various fiscal periods in 2017 and 2016, presented on the same basis as the most recent quarter's reporting. This is intended to help investors analyze the impact of the structural changes.